Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This was a prospective, single center, open label, randomized study evaluating the biological
effect of squalamine lactate ophthalmic solution, 0.2% combined with intravitreous
ranibizumab in patients with macular edema secondary to branch, hemi-central and central
retinal vein occlusion (BRVO, HRVO, CRVO).